Stay in tune with the growing changes in drug access and regulatory transparency, including rising insurance denials for brand-name medications and FDA updates around rejection letters and advisory committees. Read on for a closer look at developments shaping the biopharma industry.
Brand-Name Drug Denials Surge, Especially for Weight Loss
Source: PharmaVoice
Insurance denials for brand-name prescription drugs have risen sharply, with formulary-based rejections up 67% between 2018 and 2024. Weight-loss medications like Wegovy face the steepest barriers, with first-attempt approval rates around just 15%, largely due to formulary restrictions and utilization management rules.
What’s in the FDA’s Latest Batch of Rejection Letters
Source: PharmaVoice
A newly released batch of FDA complete response letters shows that most recent rejections stemmed from product quality and facility issues rather than clinical concerns, with some letters so heavily redacted that entire sections were unreadable. Ongoing questions remain about the legal basis for the agency’s transparency push.
FDA Has Recommitted to AdComms, But to What End?
Source: BioSpace
The FDA has renewed its commitment to convening advisory committees for drug reviews, though the purpose and consistency of this approach remain unclear. The shift raises questions about how external expert input will factor into regulatory decisions moving forward.
